Six-month remission rates with biosimilar versions of rituximab were similar to those seen with the original therapy among adults with the two most common types of ANCA-associated vasculitis (AAV), according to a real-world study in Canada. Data also showed no significant differences in serious adverse events or AAV-related…
News
The presence of clumps of inflammatory cells, or granulomas, in the liver is a rare manifestation of ANCA-associated vasculitis (AAV) that varies widely and can be difficult to diagnose, according to the findings of a new study from Tunisia. While liver problems are common in AAV, the researchers noted…
Free-floating CD95L, a protein involved in inflammation and immune responses, is found at significantly higher levels in the blood of people with ANCA-associated vasculitis (AAV) and may be a potential treatment target, according to a study in France. Through a detailed series of experiments, researchers figured out that CD95L…
Mirador Therapeutics has secured worldwide development and commercialization rights to KP-301, an experimental long-acting antibody therapy licensed from Kira Pharmaceuticals, and plans to develop it for ANCA-associated vasculitis (AAV). KP-301 is a long-acting antibody that blocks C5a, a protein in the complement system that helps drive inflammation and small…
Kidney biopsy findings may help identify which adults with severe kidney involvement due to ANCA-associated vasculitis (AAV) are more likely to recover kidney function after treatment, a small study suggests. Data showed that patients with better kidney function at one year had a higher percentage of normal glomeruli —…
Hearing loss is common among people with two types of ANCA-associated vasculitis (AAV), affecting half of those assessed in a small study in Saudi Arabia, according to researchers. Following audiological and other assessments, the team found loss of hearing in about 50% of participants with granulomatosis with polyangiitis (GPA)…
A study linked higher blood levels of tiny sacs carrying immune proteins from the complement system — which is known to contribute to ANCA-associated vasculitis (AAV) — to kidney involvement and damage in AAV patients. The findings could help doctors detect kidney disease in people with AAV and develop…
The U.S. Food and Drug Administration (FDA) has cleared the start of clinical testing of FT839, Fate Therapeutics’ experimental off-the-shelf CAR T-cell therapy for ANCA-associated vasculitis (AAV) and other autoimmune disorders. The company plans to launch a basket Phase 1/2 clinical trial to evaluate FT839 in combination with…
Blood cell ratios derived from routine blood tests may help distinguish people with active ANCA-associated vasculitis (AAV) from those in glucocorticoid-free remission, independent of age and sex, according to a new study. “Our findings suggested that these readily available, standardized, low-cost biomarkers make them attractive candidates for integration into…
Black people with ANCA-associated vasculitis (AAV) were diagnosed at a younger age than white people and tended to show more signs of kidney disease severity, according to a study in the U.S. “These findings suggest that [variability] in disease presentation within the spectrum of AAV highlights the importance of examining…
Recent Posts
- Biosimilar therapy shows similar 6-month remission rates in AAV
- Finding clump of cells in liver in AAV is ‘rare but genuine,’ per new study
- Why EGPA should be included in more ANCA vasculitis clinical trials
- Study identifies inflammatory protein as potential treatment target in AAV
- Mirador licenses long-acting antibody therapy for AAV development